Reports and Briefs on Immunology and Inflammation in North America

The following industries match your search criteria:

Published within

« | 1 | 2 | » »|

Results are sorted by relevance. Click on heading titles to sort results by different field.

Type Product title / description Pub Price
Report
Report

Commercial Insight: Osteoporosis - Market players maximize revenue growth before the next challenging phase

Comprehensive analysis of the current and future osteoporosis drug market, with country-specific forecasts to 2019 of marketed, generic, and key pipeline drugs in the seven major markets (US, Japan, France, Germany, Italy, Spain and the UK).

Published By Datamonitor
21 Jul 2010 $15200
Buy
Report
Report

Stakeholder Insight: Rheumatoid arthritis - Rising competition by line and severity

Datamonitor surveyed 183 rheumatologists in the seven major markets to gain insight into rheumatoid arthritis diagnosis, patient segmentation, current and future prescribing patterns, factors influencing decision making and key treatment challenges.

Published By Datamonitor
17 Sep 2010 $15200
Buy
Report
Report

Commercial Insight: Inflammatory Bowel Disease - Future market prospects rely on addressing cost and safety

Coverage of the inflammatory bowel disease (IBD) market, including indication-specific 10-year forecasts, detailed brand profiling, opportunities and threats, and a scenario-based case study.

Published By Datamonitor
05 Aug 2010 $15200
Buy
Report
Report

Stakeholder Opinions: Therapeutic Vaccines - A far-off promise of greatness

This report assesses the current landscape of and future opportunities for therapeutic vaccines outside cancer, covering therapeutic vaccine approaches in cardiovascular and metabolic, CNS, autoimmune and infectious diseases.

Published By Datamonitor
17 Dec 2009 $3800
Buy
Report
Report

Forecast Insight: Fibromyalgia - Regulatory caution threatens EU market expansion

Provides analysis of key events and their impact on the fibromyalgia market over the last year (July 2008June 2009). Includes indication- and country-specific 10-year forecasts of key marketed, generic, and pipeline products to 2018.

Published By Datamonitor
03 Jun 2009 $15200
Buy
Report
Report

Product Profiles: Psoriasis – Novel therapies raise the bar for biologics

This report analyzes key marketed and pipeline agents for psoriasis, including the current market dynamics of topical, oral and biologic products, key lifecycle management strategies, as well as clinical trial data from 2011 dermatology conferences.

Published By Datamonitor
23 Nov 2011 $11400
Buy
Report
Report

Market and Product Forecasts: Disease Modification in Rheumatoid Arthritis – Novel therapies plus reformulations poised to enter the market

Focusing on disease-modifying drugs, Datamonitor uses a patient-based approach to size the seven major rheumatoid arthritis markets from 2010 to 2020. Robust epidemiology forecasts, survey data and opinion leader discussions validate key assumptions.

Published By Datamonitor
08 Sep 2011 $11400
Buy
Report
Report

Market and Product Forecasts: Systemic Lupus Erythematosus – Benlysta approval kicks off new era in lupus treatment

Benlysta’s US and EU approvals will change the lupus market considerably. With additional products moving through the pipeline, Datamonitor expects to see a significant shift from off- to on-label treatment over the next 10 years.

Published By Datamonitor
22 Aug 2011 $11400
Buy
Report
Report

Prescribing Influences: Multiple Sclerosis - Therapies that reverse neuronal damage are most sought after

This report analyzes the unmet needs of multiple sclerosis treatment and the attributes of drugs that influence prescribing decisions. The analysis aims to understand the opportunities in the market and support the positioning of marketed brands.

Published By Datamonitor
09 Aug 2011 $5700
Buy
Report
Report

Commercial Insight: Disease Modification in Rheumatoid Arthritis – Market awaits game changing therapies and strategies

Coverage of disease-modifying drugs in the seven major rheumatoid arthritis markets, including indication-specific 10-year forecasts (using both sales and patient-based approaches), detailed brand profiling and an in-depth patient-based case study.

Published By Datamonitor
15 Dec 2010 $15200
Buy

« | 1 | 2 | » »|

No help is available.